NNIT Slashes 2026 Outlook Amid Life Science IT Slowdown
Event summary
- NNIT reports Q1 2026 revenue of DKK 422.5m, down 7.3% in constant currency vs. Q1 2025.
- Group EBIT margin excluding special items drops to 0.3% from 3.9% YoY.
- 2026 outlook revised: single-digit negative revenue growth (previously 0-5% growth) and EBIT margin of 4-7% (previously 6-9%).
- Geopolitical turmoil and customer caution in Life Science IT consulting cited as key drivers.
- Special items now expected to be 'below last year’s level of DKK 83m' (previously 'significantly below').
The big picture
NNIT’s downgrade reflects broader caution in the Life Science IT consulting sector, where geopolitical uncertainty and delayed projects have pressured revenue. The company’s focus on operational efficiency and cost reduction suggests a defensive posture as it navigates a challenging market environment. The scale of the revision—particularly the shift to negative revenue growth—highlights the severity of the slowdown in a core segment.
What we're watching
- Revenue Recovery
- Whether NNIT can stabilize revenue growth amid sustained customer caution in Life Science IT.
- Cost Optimization
- The pace at which NNIT reduces its full cost base to improve EBIT margins.
- Geopolitical Impact
- How continued geopolitical turmoil affects project timelines and contract sizes in key markets.
Related topics